×
About 915 results

ALLMedicine™ Exfoliative Dermatitis Center

Research & Reviews  42 results

Dermatologic Manifestations of Staphylococcal Scalded Skin Syndrome
https://emedicine.medscape.com/article/1053325-overview

Mar 15th, 2022 - Practice Essentials Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated exfoliative dermatitis. Toxin-mediated staphylococcal syndromes comprise a group of blistering skin diseases, ranging in severity from localized bullous impetigo t...

Dermatologic Manifestations of Staphylococcal Scalded Skin Syndrome
http://emedicine.medscape.com/article/1053325-overview

Mar 15th, 2022 - Practice Essentials Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated exfoliative dermatitis. Toxin-mediated staphylococcal syndromes comprise a group of blistering skin diseases, ranging in severity from localized bullous impetigo t...

Dermatologic Manifestations of Staphylococcal Scalded Skin Syndrome
https://emedicine.medscape.com/article/1053325-print

Mar 15th, 2022 - Practice Essentials Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated exfoliative dermatitis. Toxin-mediated staphylococcal syndromes comprise a group of blistering skin diseases, ranging in severity from localized bullous impetigo t...

Exfoliative Dermatitis
https://emedicine.medscape.com/article/762236-overview

Jun 22nd, 2021 - Practice Essentials Exfoliative dermatitis is characterized by generalized erythema with scaling or desquamation affecting at least 90% of the body surface area. Systemic derangements may occur with exfoliative dermatitis, including peripheral ede...

Exfoliative Dermatitis
https://emedicine.medscape.com/article/762236-print

Jun 22nd, 2021 - Practice Essentials Exfoliative dermatitis is characterized by generalized erythema with scaling or desquamation affecting at least 90% of the body surface area. Systemic derangements may occur with exfoliative dermatitis, including peripheral ede...

see more →

Drugs  313 results see all →

Clinicaltrials.gov  2 results

sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN
https://clinicaltrials.gov/ct2/show/NCT02271724

May 16th, 2016 - Chronic inflammatory peripheral neuropathies are characterized by progressive deterioration in muscle strength, loss of sensibility, diminished or absent reflexes and impaired fine motor control. Often it is caused by demyelination which is suitab...

Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00748319

Aug 22nd, 2012 - Background : The most frequent cutaneous T-cell lymphomas (CTCL) are mycosis fungoid and Sezary syndrome. Both are due to the proliferation of a CD4+ T-cell clone in the skin, associated with a blood involvement in Sezary syndrome. Mycosis fungoid...

see more →

News  7 results

EU Approves Midostaurin for AML, Advanced Systemic Mastocytosis
https://www.onclive.com/view/eu-approves-midostaurin-for-aml-advanced-systemic-mastocytosis

Nov 13th, 2020 - Bruno Strigini, CEO The European Commission has approved midostaurin (Rydapt) for adults with newly diagnosed FLT3-positive acute myeloid leukemia (AML) and advanced systemic mastocytosis (SM), including aggressive systemic mastocytosis (SM), SM ...

FDA approves bevacizumab-bvzr for several cancers
https://www.mdedge.com/hematology-oncology/article/203812/gynecologic-cancer/fda-approves-bevacizumab-bvzr-several-cancers
Laura Nikolaides

Jun 28th, 2019 - The Food and Drug Administration has approved bevacizumab-bvzr (Zirabev) – a biosimilar to bevacizumab (Avastin) – for the treatment of five cancers: metastatic colorectal cancer (mCRC); unresectable, locally advanced, recurrent or metastatic non-.

FDA approves biosimilar to bevacizumab
https://www.mdedge.com/chestphysician/article/147160/gastroenterology/fda-approves-biosimilar-bevacizumab
Laura Nikolaides, MDedge News

Sep 14th, 2017 - The Food and Drug Administration has approved a biosimilar to bevacizumab (Avastin) for the treatment of certain colorectal, lung, brain, kidney, and cervical cancers. Bevacizumab-awwb is the first biosimilar approved in the United States for the.

First Oncology Biosimilar Approved in US: Bevacizumab
https://www.medscape.com/viewarticle/885684

Sep 14th, 2017 - The US Food and Drug Administration (FDA) has approved the first biosimilar for use in oncology ― the product is Mvasi (bevacizumab-awwb), from Amgen. It is equivalent to the reference product, Avastin (Genetech/Roche), which was first approved in...

Imatinib Mesylate–Induced Lichenoid Drug Eruption
https://www.mdedge.com/dermatology/article/132728/nonmelanoma-skin-cancer/imatinib-mesylate-induced-lichenoid-drug-eruption
Erin H. Penn, MD, Hye Jin Chung, MD et. al.

Mar 6th, 2017 - Imatinib mesylate is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). The indications for imatinib have expanded since its initial approval.

see more →

Patient Education  2 results see all →